I. INTRODUCTION
It is now a quarter century since Akinori Noma (305) first described ATP-sensitive K ϩ (K ATP ) currents in cardiac myocytes. In the intervening years, details of the signature inhibition of K ATP by ATP, activation by MgADP, and pharmacological modulation by inhibitory sulfonylureas, and potassium channel opening (KCO) drugs, have been clarified and are described in earlier reviews (13, 295, 299, 385) . The cloning of genes encoding the underlying subunits, in the mid 1990s (2, 56, 168, 171) , led to a detailed molecular dissection of channel function and regulation and insights to the tissue-specific nature and regulation of these channels. Here we review these advances in understanding of the molecular structure and physiological function of cardiac, skeletal, and smooth muscle K ATP , with a particular focus on the insights that have been gained over the last 10 years, driven in large part by the generation of knockout mouse models for each of the K ATP genes (KCNJ8, KCNJ11, ABCC8, ABCC9) (55, 275, 360, 362) and transgenic mice with altered K ATP function (114, 219, 260). These studies have pointed to muscle-specific roles of K ATP channels, including ischemic protection in the heart, protection against fiber damage in skeletal muscle, and control of vasomotor tone in smooth muscle. Unlike the pancreatic ␤-cell, where human disorders clarify the physiological role of K ATP in glucose-dependent insulin secretion (126, 221, 379) , no consistent picture has yet emerged of human myopathic disease resulting from altered K ATP activity. However, there are compelling findings and correlations that implicate not only an important physiological role for K ATP , but potential pathophysiological roles in disease states.
A. Molecular Basis of K ATP Channel Activity
K ATP channels are heteroctameric complexes of pore-forming Kir channel subunits together with members of the ATP binding cassette (ABC) family of membrane proteins (Fig. 1) . Two genes, KCNJ8 (Kir6.1) and KCNJ11 (Kir6.2), encode K ATP pore-forming subunits (167, 168), while two SUR genes, ABCC8 (SUR1) and ABCC9 (SUR2), generate regulatory subunits (2, 56, 168) . Alternative RNA splicing gives rise to several SUR protein variants (e.g., SUR2A and SUR2B) that confer distinct physiological and pharmacological properties on the channel complex (53, 365). Interestingly (Fig. 1D) , the genes for Kir6.2 and SUR1 are located next to each other on human chromosome 11p15.1 (168), suggesting an as yet unconsidered coregulation at the gene level. In addition, the genes for Kir6.1 and SUR2 are also adjacent to one another on chromosome 12p12.1 (56, 170), implicat-FIG. 1 . The structural basis of K ATP channel activity. A: K ATP channels are formed from Kir6 (left) and SUR (right) subunits. Kir6 consists of a tetrameric arrangement of subunits, each consisting of two transmembrane helices (M1, M2), a pore-forming region (including the P-helix and selectivity filter), and cytoplasmic NH 2 terminus (including the amphipathic slide helix) and COOH terminus. SUR consists of the TM0 and L0 regions that interact with and mosulate gating of Kir6, followed by two additional 6-helix TM regions, each followed by a nucleotide binding fold (NBF). The two nucleotide binding folds come together to generate two nucleotide interacting sites at their interface. B: the K ATP channel is an octameric structure of Kir6 and SUR subunits. C: Kir6 and SUR can be modeled on the structure of other prokaryotic and eukaryotic proteins. Such structures predict one ATP binding site at each of the Kir6 interfaces and Mg-nucleotide binding sites in the dimeric NBF structures of SUR. D: human SUR and Kir6 gene structures indicate that each pair is located adjacent to each other on two chromosomes.
ing an evolutionary duplication event. To recapitulate K ATP channel activity in a heterologous expression system, both Kir6 and SUR subunits must be coexpressed (168), and biophysical and biochemical studies show that Kir6.2 and SUR1 subunits combine in a 4:4 stoichiometry ( Fig. 1) to generate the functional K ATP channel (60, 169, 373) . Similarly, biochemical studies demonstrate that the SUR2 protein variants, SUR2A and SUR2B, can also coassemble with Kir6 subunits (20, 167, 311, 442) , presumably in a similar octameric arrangement.
The Kir6 subunit
Kir6.1 and Kir6.2 are typical inward rectifier channel proteins consisting of two transmembrane helical domains, TM1 and TM2, and cytoplasmic NH 2 and COOH termini (Fig. 1C) . The two transmembrane helices and pore domain of Kir6.1 and Kir6.2 ( Fig. 1C) share significant structural similarity to the pore-forming S5-S6 membrane segment of voltage-gated K ϩ channels. Both Kir subunits contain a highly conserved sequence of residues called the K ϩ channel signature sequence (TVGY/FG) (152), which confers K ϩ selectivity and is found throughout the K ϩ channel family. While the same general pore structure is predicted for both Kir6.1 and Kir6.2, the two subunits exhibit distinct single-channel conductances of ϳ35 and ϳ80 pS, respectively, in 150 mM K ϩ solutions (167, 168, 178, 216, 442) , conferred by specific residues in the TM1-TM2 regions (341) .
The signature property of K ATP is inhibition by intracellular ATP with ATP binding occurring on the Kir6 subunit (92, 239, 374, 410, 411) . Heterologously expressed K ATP channels comprised of Kir6.2 plus SUR1 or SUR2A close in the presence of ATP with an average K 1/2 for inhibition of ϳ10 M (298). Although initially reported to be insensitive to ATP (442) , Kir6.1-containing channels have since been shown to exhibit ATP inhibition comparable to Kir6. 2 (18, 356) . Both nonhydrolyzable ATP analogs and ATP inhibit K ATP channels, confirming that inhibition is not a consequence of phosphorylation, but of direct binding to the channel (110, 197, 237) . In the absence of Mg 2ϩ , ADP also blocks channel activity (197, 237, 305) , albeit with lower affinity, suggesting that electrostatic interactions with the phosphate moieties on the ATP molecule, particulary the ␥-phosphate, are important for binding (187) .
Following the publication of the structure of the tetrameric cytoplasmic domains of eukaryotic Kir3.1 (304), and of the full-length bacterial homolog KirBac1.1 (231), modeling of the tetrameric Kir6 pore revealed that threedimensional folding brings several residues in the cytoplasmic NH 2 and COOH termini together (R50, R201, G334, II82) to form a binding pocket for ATP (Fig. 1C) (8, 103, 188, 342, 406) , for a total of four binding sites per channel (i.e., each Kir subunit in the tetrameric pore binds one molecule of ATP) (8, 103, 136, 406) . In addition, the NH 2 terminus contains an amphipathic "interfacial" or "slide" helix, predicted to lie parallel to the inner surface of the lipid membrane (Fig. 1 , A and C) (102). This slide helix is physically coupled to the cytoplasmic end of the pore and may provide the physical link between ATP binding and the gate of the channel, which is likely to be located at the crossing point of the inner helix bundle (230, 231, 321, 343) . More detailed homology models of Kir6.2 continue to follow the appearance of more refined bacterial channel structures (KirBac3.1) and eukaryotic channel cytoplasmic domains (Kir3.1, Kir2.1) (230, 231, 273, 304, 321). Mikhailov et al. (273) have successfully purified a Kir6.2/SUR1 complex and provided a low-resolution structure using single-particle electron microscopy, but direct crystallographic analysis of the K ATP channel pore structure has thus far been unattainable.
The SUR subunit
In the absence of Mg 2ϩ , nucleotides inhibit K ATP channel activity, but in the presence of Mg 2ϩ , both ATP and ADP stimulate channel activity (95, 160, 196, 237) , through interaction with the SUR subunit (132, 303, 372) . The unifying structural feature of all ABC proteins is the cytoplasmic nucleotide binding folds, NBF1 and NBF2, comprised of Walker A and Walker B nucleotide-binding motifs and other conserved sequences (154) (Fig. 1C) . The NBF domains contain the binding sites for Mg 2ϩ -adenosine nucleotides that serve to stimulate K ATP function (48, 264). In the ABC superfamily, the transmembrane domains (TMD1, 2), each comprised of six transmembrane helices, typically carry out transmembrane transport function. However, SUR1 and SUR2 are atypical in that no such transport function has been identified, and these subunits contain an additional transmembrane domain at the NH 2 terminus, TMD0, that is joined to TMD1 by a cytoplasmic linker L0 (Fig. 1) . Physical interaction between the cytoplasmic NH 2 terminus of Kir6.2 and the TMD0 domain of SUR, including the cytoplasmic L0 linker, is demonstrated to be important in regulation of Kir6.2 gating by SUR (19).
In bacterial ABC proteins, dimerization of NBFs is favored by the presence of nucleotides, and ATP hydrolysis requires cooperative interactions of the two NBFs (233, 380), leading to the hypothesis that the nucleotidebound dimer is the catalytically active species. By analogy, it is suggested that Mg 2ϩ -dependent ATP hydrolysis at the dimeric SUR NBFs provides the "power stroke" that overcomes the inhibitory effect of ATP on Kir6. The Mg 2ϩ dependence of ␣ 32 P-and ␥ 32 P-azido-ATP labeling of SUR NBFs suggests that SUR NBFs also hydrolyze ATP (266, 412) . Trapping of channels in the activated state by vanadate (a transition-state analog that mimics a posthydrolytic, ADP-bound state) and in an inactivated state by beryllium fluoride (a transition-state analog that mimics the prehydrolytic, ATP-bound state) (460) further support the hypothesis that ATP hydrolysis underlies channel activation in intact cells, where ATP concentrations will always be at millimolar levels, even when metabolism is substantially inhibited (98). However, direct measurements of nucleotide hydrolysis by SUR NBFs are sparse (37, 263, 273, 460) , and SUR-NBF mutations analogous to those that have drastic effects on ATP hydrolysis in bacterial NBFs have only modest effects on SUR-mediated hydrolysis (37). In membrane patch-clamp experiments, channel activation by exogenous MgADP is much more effective than activation by MgATP, and the same "hydrolysis" mutations lead to decreased MgADP stimulation of K ATP channels (37, 132, 372, 462) . Why MgADP should so strongly activate the channel in excised patches if a hydrolytic cycle is required for activation is unclear. This would require that the "activated" state resulting from hydrolysis persists after MgADP dissociation, at least long enough for rebinding of exogenous MgADP to maintain the state. Just how reasonable this notion is has not been addressed, and it remains conceivable that hydrolysis, if it occurs, is an epiphenomenon and that preferential binding of MgADP at the second nucleotide binding site is actually the physiological activator of the channel.
Additional subunits of K ATP and macromolecular complexes
In addition to different gene products, SUR splicing may also be important in determining channel function (53, 142, 350, 365) . Expression of SUR1 splice variants with deletions of TM16/17 (133), in NBF1 (142), and in NBF2 (350) have been reported in the heart. Alternative splicing of SUR2 exons 14 and 17, leading to deletion of segments of NBF1, is also expressed in the heart (53). The functional significance of these variants is not known, although channels containing SUR2A ⌬exon17 are reportedly less sensitive to ATP inhibition (53). In addition, the recent identification of short-form or partial SUR2 gene products (328) has arisen from studies of the SUR2 Ϫ/Ϫ mouse. The targeting construct used in the generation of these animals contained a replacement of exons 12-16, coding for regions of NBF1 (55). Naturally transcribed short-form SUR2 subunits lacking the NBF1 domain have been identified using antibodies raised against distal parts of the protein (329, 388) and are reported to coassemble with Kir6.1 and Kir6.2 to form glibenclamide-insensitive, ATP-sensitive, currents in ventricular myocytes (328) . A further recent study provides evidence that these short forms are present in mitochondria and, therefore, may actually be a component of "mitoK ATP " (449) .
While the coassembly of Kir6x and SURx is sufficient to reiterate hallmark properties of K ATP channels, additional proteins may also contribute to a macromolecular channel complex and fine-tune channel function. Recent studies have implicated an elaborate ␤-cell K ATP channel macromolecular structure (318, 368) , and there is mounting evidence that metabolic enzymes, including adenylate kinase (AK) (49), creatine kinase (CK) (73), and lactate dehydrogenase (LDH) (71), can physically associate with, and regulate, the cardiac K ATP channel complex. Formation of a multiprotein complex (Fig. 2 ) that includes both phosphotransfer and glycolytic enzymes (89, 191) may explain early studies of the native sarcolemmal channel, in which direct application of glycolytic substrates to excised membrane patches inhibited K ATP channel activity (426, 427) . Recent studies further demonstrate the importance of a local phosphotransfer network in regulating K ATP channel activity (363) : by amplifying small changes in cytoplasmic ATP concentration, AK and CK may play an integral role in regulating the nucleotide concentration in the localized membrane environment (Fig. 2) , thereby regulating the K ATP response to metabolic events. In the cell, glycolysis can oscillate periodically, driven by feedback loops in regulation of key glycolytic enzymes by free ADP and other metabolites (155, 309, 444) . Several studies have shown that when the capacity to buffer cellular ATP and ADP levels is suppressed by metabolic inhibition, oscillations in glycolysis can cause concurrent oscillations in ventricular action potential duration, due to oscillatory activation of K ATP (9, 309, 310, 444), which may promote arrhythmias during acute metabolic stresses, such as myocardial ischemia.
Modulation by cellular lipids, metabolites, and protein kinases
Nucleotide regulation is the signature property of K ATP , although other regulatory ligands modulate channel activity through direct interaction with the Kir6 subunit, the SUR subunit, or both. Membrane phospholipids, phosphoinositides, in particular, e.g., phosphatidylinosital 4,5-bisphosphate (PIP 2 ), potently stimulate K ATP activity by binding the Kir6.2 subunit (29, 107, 344, 375, 439). Application of PIP 2 directly to the intracellular side of excised membrane patches leads to significant increase in K ATP channel activity and restores channel activity after channel "rundown" (107, 156). Conversely, treatment of a patch with phospholipase C (PLC), to hydrolyze PIP 2 , reduces channel activity (107, 156). Similarly, receptor-mediated activation of PLC modulates K ATP activity in recombinant cell systems where receptor and channel proteins are overexpressed (29, 438), although direct support for a dynamic regulation in native muscle cells is lacking. Importantly, there exists a negative coupling between PIP 2 activation and ATP sensitivity of K ATP channels such that as PIP 2 increases, channel open probability increases and ATP sensitivity decreases (103). Physiologically, this means that ATP sensitivity is not a fixed parameter and may change dynamically with changes in membrane composition. Residues involved in PIP 2 binding and activation overlap with the ATP binding site on Kir6.2, consistent with their competitive effects observed in binding assays (103, 258, 344) . The activation of channels by PIP 2 requires the presence of both the headgroup and the phospholipid tail, since the cleavage products of PIP 2 hydrolysis (IP 3 and diacylglycerol) have little effect on channel activity. The negative charge of the head group is also critical, since phosphatidylserine (net negative charge) can activate K ATP but phosphatidylcholine (net positive charge) cannot (107). Consistent with an electrostatic interaction between the negatively charged head group and a region of the Kir6.2 protein close to the membrane, a number of positively charged amino acid residues in the slide helix region directly interact with PIP 2 in the membrane (79, 80, 358, 374) . While PIP 2 interaction with Kir6.1 has been less extensively studied, Kir6.1 channels are activated by PIP 2 (335) , suggesting conservation of the fundamental determinants of phospholipid binding and gating (164, 347, 455) .
Long-chain acyl-coA molecules (LC-CoA), intermediates of ␤-oxidation of fatty acids, have also been shown to modulate K ATP channel activity in an analogous manner to membrane phosphoinositides (249). The same residues on Kir6.2 that mediate PIP 2 activation also contribute to the stimulatory effect of LC-CoA (262, 358), suggesting that Kir6.2 is the major site of LC-CoA action. The effect of LC-CoA on ATP sensitivity is greater in ventricular myocytes than in pancreatic ␤-cells (43, 44, 117, 235), and the degree of acyl-coA activation increases with chain length for cardiac ventricular channels, while in pancreatic ␤-cells, mediumchain fatty acyl moieties seem to be less effective. PIP 2 FIG. 2. Complexities of K ATP channel regulation in striated muscle. The balance of ATP synthesis and usage, reflected by ATP and ADP levels, is the major direct determinant of channel activity (box). Metabolic enzymes, including adenylate kinase (AK), creatine kinase (CK), and lactate dehydrogenase (LDH), in the cytoplasm and physically associated with the channel may serve to amplify metabolic changes, or locally buffer and control ATP/ADP levels, thereby fine-tuning channel activity. Nonnucleotide ligands, including PIP 2 , acyl-CoA, and H ϩ , may also play a key role. PIP 2 and acyl-CoAs have powerful stimulatory effects that are antagonistic to ATP inhibition. In addition, hormone receptor activation can lead to protein phosphorylation (P) with both stimulatory and inhibitory effects on the channel. However, none of these molecules acts in isolation, and the resultant K ATP channel activity is an integrated response to a myriad of interrelated metabolic signals.
and lipid modulation of ATP sensitivity is a very powerful modulator of channel activity, and changes of lipids in pathophysiological conditions may be an important regulator. Since cardiac ventricular K ATP is predominantly SUR2A dependent, whereas the pancreatic K ATP is predominantly SUR1 dependent (see below), the distinct effects of acyl-CoA on cardiac ventricular and pancreatic channels suggest that there is also a role for differential SUR involvement in determining the activation properties of the lipid metabolites, although this needs further work and the implications remain unclear.
Acidic intracellular pH stimulates K ATP channel activity (87, 88, 440), and intracellular acidification concomitant with anaerobic metabolism provides another potential physiological stimulus of K ATP activity. The mechanistic basis of pH regulation is still not completely established, although there is a general consensus that protons act to decrease sensitivity to inhibitory ATP. Mutagenesis studies of recombinant Kir6.2 subunit have revealed two amino acids (Thr-71 and His-175) that appear to be critical determinants of pH sensing (76, 437), but it remains unclear whether these residues are directly protonated and how they regulate the effect of pH on ATP-dependent gating.
Agonist-dependent, protein kinase A (PKA) phosphorylation is an important regulator of smooth muscle K ATP channels and of pancreatic K ATP , although the importance of channel phosphorylation is not entirely clear in striated muscle. The Kir6.2 subunit has two consensus PKA phosphorylation sites (33) which when phosphorylated increase channel open probability (33, 247). In human SUR1, a unique, constitutively phosphorylated PKA site acts to both increase the surface expression of the channel and decrease channel open probability, although this residue is not conserved in rodent SUR1 (33). The specific effects of PKA on Kir6.2/SUR2A combinations have not been examined, and it is unknown whether the potential PKA sites of SUR2A are phosphorylated and what effect, if any, this might have on channel activity in striated muscle, where these subunits are predominant. In contrast, the physiological role of PKA-dependent activation of K ATP channels in vascular smooth muscle is now established, and phosphorylation of both Kir6.1 and SUR2B appear to be critical in regulating channel activity, and hence vascular tone (see sect. IV).
Protein kinase C (PKC) has mixed actions on native ventricular K ATP channels, inhibiting at low micromolar ATP concentrations (242), but activating at high ATP concentrations (246), through phosphorylation of highly conserved T180 residue in the Kir6.2 subunit (243). Chronic PKC activation also stimulates the retrieval of Kir6.2 from the surface membrane through a dynamindependent mechanism (162). Kir6.1/SUR2B channels are inhibited (335) by acute PKC treatment, due to phosphorylation of residues in Kir6.1 (see sect. IV), whereas Kir6.2/ SUR2B channel activity is reportedly unaffected by PKC (366, 402) , highlighting the specificity of K ATP channel subunit combinations in physiological regulation.
Structural basis of K ATP pharmacology
The SUR subunit also determines the sensitivity of the channel to a huge range of pharmacological KCOs and blockers (2, 17, 21, 22, 37, 82, 139, 282, 292, 413) . All SUR isoforms are inhibited by the sulfonylurea glibenclamide, with sulfonylurea inhibition being dependent on nucleotide concentrations, and hence on metabolic state (223, 339). SUR1 is typically more sensitive to sulfonylureas than SUR2 (131), a difference that has been exploited with SUR1/2 chimeric constructs to implicate a binding site for tolbutamide in TMD2 of SUR1 (17, 22). Mutation of residue S1237 in SUR1 to tyrosine, the analogous residue in SUR2, reduces the affinity for tolbutamide and gliblenclamide (17), while the reverse mutation (Y1206S in SUR2) increases affinity (141). The SUR subunits confer also sensitivity to KCOs such as diazoxide, cromakalim, and pinacidil (298). Diazoxide is an effective activator of SUR1 and SUR2B, but not SUR2A, whereas pinacidil and cromakalim are effective activators of SUR2A and SUR2B, but not SUR1 (112, 333), highlighting the potential for tissue specificity, which remains an important pharmaceutical strategy (15). The channel openers typically contain one or more nitrogen-substituted aromatic rings and include derivatives of cyanogaunidines (e.g., pinacidil), benzopyrans (e.g., cromakalim), but also many others, and a common pharmacophore has proven elusive (61, 261). Regions important for KCO action are spread throughout the SUR subunits and include TMD1 and NBD1 for diazoxide (21) and TMD2 for cromakalim and pinacidil (140, 282, 413) . These openers all require the presence of hydrolyzable ATP (90, 140, 359) , which suggests that they act to stabilize or enhance ATP hydrolysis at the NBFs.
II. K ATP IN CARDIAC MUSCLE
Under normal physiological conditions, voltage-gated K ϩ channels and I K1 , the strong inward rectifier current, provide the major repolarizing current and stabilize the cardiac resting potential (297), while K ATP channels seem to play little or no role in regulating heart rhythm or contraction, despite the fact that they are the most densely expressed K ϩ channel and if fully activated can lead to complete cessation of cardiac electrical activity and contractile failure (237, 238). Recent studies, taking advantage of genetically altered mice, are providing unique insight into the molecular mechanisms of cardioprotection and surprising revelations about the molecular basis of K ATP channel activity. (361, 405, 414) , although this could be due to heterologous assembly with endogenous Kir6.2 subunits during channel turnover, and K ATP current in ventricular myocytes is apparently unaffected in Kir6.1 Ϫ/Ϫ mice, further arguing against a role for Kir6.1 in native sarcolemmal K ATP (276).
SUR1 and SUR2 subunits can also coassemble within the same channel complex (50, 51, 431), and both SUR1 mRNA and protein have been detected in the hearts of various species (177, 284, 285, 322, 350, 381, 450) . K ATP channel activity is unaffected in ventricular myocytes from SUR1 Ϫ/Ϫ mice (100, 112), yet antisense oligonucleotides specifically directed at SUR1 markedly reduce rat neonatal ventricular K ATP current density (450) . It is important to recognize that the molecular architecture need not be static and may change in response to metabolism or other signals. For example, hypoxia increases SUR2A subunit expression in cultured rat heart H9C2 cells (72), and SUR1 expression and diazoxide-sensitive current are both increased in infarcted heart regions (177). In addition, Kir6.1 mRNA expression is significantly elevated following myocardial ischemia or hypoxia, raising the possibility that Kir6.1 protein may be upregulated in myocytes in response to stress (177, 271). At this juncture, whether the increase in Kir6.1 in the heart during cardiac disease reflects increased expression specifically in cardiac myocyte or other cell types remains uncertain.
Atrial sarcolemmal K ATP structure
Comparatively few studies have examined the biophysical and pharmacological properties of K ATP channel in atrial myocytes, but the work that has been done suggests that the structure of atrial and ventricular K ATP are distinct. We have recently demonstrated that SUR1 protein is present in wild-type mouse atrial myocytes and that K ATP currents are undetectable in atrial myocytes from SUR1 Ϫ/Ϫ mice (112), providing unequivocal evidence for an essential role of SUR1 in the atrial sarcolemmal K ATP channel in mice (Table 1 ). In agreement with this conclusion, native atrial K ATP is more sensitive to diazoxide than pinacidil, similar to recombinant SUR1/ Kir6.2, while the ventricular channel exhibits the opposite specificity (112, 127), similar to recombinant SUR2A/ Kir6.2. Although genetic proof by knockout of specific subunits is not possible in other species, there is some evidence for chamber-specific K ATP pharmacology in other species. For instance, K ATP channels in neonatal rat atrial myocytes are significantly more sensitive to activation by metabolic inhibition and diazoxide than are ventricular K ATP channels, as would be expected for SUR1-containing channels (26, 324). The functional implication of disparate structure of atrial and ventricular K ATP is unclear, but conceivably, SUR1-based channels are necessary for an atrial specific function, such as coupling atrial stretch with the secretion of atrial natriuretic peptide (186, 206, 348, 441) . Interestingly, atrial K ATP channels have been reported to be activated by stretch (214, 326, 416) , although the data are sparse, and the finding that atrial Kir3.4 channels are also stretch sensitive (173) may provide an alternative explanation. 
Nodal and

Molecular basis of mitoK ATP
The major focus of this review is on sarcolemmal membrane K ATP channels, but it is necessary to also consider the mitochondrial K ATP (mitoK ATP ) channel that has also been significantly implicated in cardiac pathophysiology. A K ϩ -selective, small-conductance channel was first identified in fused giant mitoplasts from rat liver mitochondria (174) and reported to be reversibly inhibited by application of ATP, glibenclamide, and 4-aminopyridine (4-AP). Further examination revealed a number of properties that distinguish these mitoK ATP from sarcolemmal K ATP channels. First, mitoK ATP channels are reportedly inhibited by acyl-CoA and activated by GTP and GDP when ATP is also present, and second, mitoK ATP channels reconstituted into liposomes exhibited increased diazoxide sensitivity relative to reconstituted Kir6.2/SUR2A channels (123, 319). Collectively, these observations implicate an ATP-sensitive K ϩ conductance in the mitochondria that is distinct from sarcolemmal channels. 378, 390, 459) . This may in part reflect the difficulty of isolating pure mitochondria. Contamination of mitochondrial preparations with sarcolemmal proteins could yield erroneous results, particularly given the abundance of K ATP channels in the sarcolemma. In addition, the biochemical and molecular analysis may be hindered by lack of specific antibodies for K ATP subunits. For example, a recent study by Foster et al. (116), which analyzed the proteins precipitated by anti-Kir6.1 antibodies from mitochondrial extracts, found that no Kir6.1 protein was detectable by mass spectrometry. Instead, NADH flavoprotein I and mitochondrial isocitrate dehydrogenase were detected in high abundance, indicating nonspecificity of the antibodies. As discussed further below, short-form SUR2 subunits lacking the NBF1 domain have been identified in cardiac cells (328) , and specifically localized to mitochondria (449), using antibodies raised against distal parts of the protein (329, 388) . Although further studies are needed, these short forms may actually be a component of mitoK ATP (449) .
Lack of confirmed presence of canonical SUR or Kir6 subunits in mitochondria has led to alternative hypotheses regarding mitoK ATP structure. Diazoxide, an activator of mitoK ATP , has been shown to inhibit succinate dehydrogenase (145). Consistent with the idea that this key enzyme of both the Krebs cycle and electron transport chain might be a component of the mitoK ATP channel, Ardehali and colleagues (10, 11) identified a macromolecular complex by coimmunoprecipitation that included succinate dehydrogenase, mitochondrial ATP-binding cassette protein-1 (mABC-1), ATP synthase, adenine nucleotide translocase, and phosphate carrier proteins that recapitulated mitoK ATP activity including diazoxide activation and 5-hydroxydecanoate inhibition. In this case, it is not clear which component should be forming the channel pore, although given the chloride channel function of the ABC protein CFTR (31), conceivably the mABC could form the pore, but the reported records show only single-channel activity over brief periods, and follow-up studies have not yet emerged.
There is now a large body of work on the pathophysiological involvement of mitoK ATP in cardiac pathophysiology and the phenomenon of preconditioning (144, 308). The above discussion reflects our own skepticism regarding the nature of the mitoK ATP , but since the interpretations of such studies lean heavily on the attendant pharmacology, the finding that diazoxide-sensitive K ATP channels are present in the sarcolemma, as well as the reconfirmation that 5-hydroxydecanoate can inhibit sarcolemmal K ATP channels (241), warrants at the least a careful reassessment of the interpretations.
B. Regulation of Cardiac K ATP Function and Implications for Heart Function
The multilevel regulation by membrane phospholipids (PIP 2 ), fatty acids (LC-acyl-CoA), protein kinases (PKA, PKC), pH, and intracellular nucleotides (ATP, MgADP) ensures complexity of metabolic sensing by K ATP channels (Fig. 2) . ATP inhibits native channel activity in excised atrial or ventricular membrane patches with an average K 1/2 of ϳ50 -100 M (110, 237, 305, 306). Several studies have demonstrated that when channels are opened by metabolic inhibition, injection of ATP into the cytosol closes channels, implicating the fall in [ATP] as a contributor to channel opening under these extreme conditions (238, 306, 395). Nevertheless, ATP probably never falls below millimolar levels in a living tissue (97), and the activating effect of Mg 2ϩ -bound nucleotide diphosphates will be important physiologically (237) so it is probably most appropriate to consider both the fall in ATP and accompanying rise in ADP as the major physiological regulatory parameters (Fig. 2) .
Additional cytoplasmic compartmentation may modify the nucleotide sensitivity in vivo. In open cell-attached patch-clamp experiments, where the cytoplasmic milieu is largely intact, channel activity is apparently less sensitive to global changes in ATP, presumably as a result of the phosphotransfer enzymes and ATP buffering capacity (300). Compartmentalization of ATP may also be important; there is a close functional colocalization of the K ATP channel and the Na ϩ -K ϩ -ATPase, such that changes in Na ϩ -K ϩ -ATP-ase activity can result in very local changes in ATP levels that are sensed by the K ATP channel (148, 193, 327) .
The roles of intracellular pH, membrane phospholipids, channel phosphorylation, and fatty acyl-CoA in the regulation of native K ATP channels in cardiac muscle are less well understood. Although recombinant Kir6.2/SUR2A channels are sensitive to a fall in intracellular pH (76, 437) as can occur during myocardial ischemia (418) , native cardiac K ATP channels are resistant to intracellular acidification by as much as 1 pH unit (75, 225, 237) and insensitive to lactate (237). Adenosine, a metabolite released from metabolically challenged myocytes, stimulates K ATP channel activity in ventricular myocytes (179, 207) through a G protein signaling cascade. PKC-dependent cardiac preconditioning by adenosine (see below) indicates an important role for adenosine-mediated K ATP channel activity in vivo, but it remains unclear whether sarcolemmal or mitochondrial K ATP or both are direct targets (63, 251, 355).
Importantly, intracellular elements other than ATP must act to keep cardiac K ATP channels closed under normal conditions to prevent AP shortening and to maintain contractility. This is made quite clear by studies of transgenic mice that express ATP-insensitive Kir6.2 subunits in the heart, such that sarcolemmal channels are ϳ100-fold less sensitive to inhibition by intracellular ATP (111, 219). In these animals, K ATP channels remain largely closed, and the action potential is not shortened under normal conditions. Conversely, expression of similar ATP-insensitive Kir6.2 transgenes in pancreatic ␤-cells suppresses electrical activity and can completely shut down insulin secretion (125, 220, 340) . Experimental studies (212, 302, 428) have consistently demonstrated that activation of only 1% of the total sarcolemmal K ATP population is sufficient to shorten the action potential by 50% and significantly reduce contractility. Computer models of the action potential, in which K ATP activity is controlled only by ATP/ADP ratios (300, 364), indicate that this would happen at low millimolar ATP and micromolar ADP levels in hearts with normal K ATP channels and that in hearts expressing the above ATP-insensitive transgenes, dramatic action potential shortening should occur at any physiological ATP levels. It thus appears that additional factors are acting to keep these channels closed in cardiac myocytes. What combination of regulatory factors that control K ATP channel opening in cardiac myocytes remains a key question.
C. K ATP in Physiology and Pathophysiology of
Cardiac Muscle: Insight From Genetically Modified Mice
Ischemia-reperfusion and myocardial infarction in K ATP null mice
Sarcolemmal K ATP channels seem to be predominantly closed and do not contribute significantly to the process of excitation-contraction coupling in physiological conditions (except perhaps under adrenergic stimulation, see below), since application of sulfonylureas generally has little or no effect on the cardiac action potential (105) and ventricular action potential duration (APD) and contractile function are unaffected in isolated ventricular myocytes from Kir6.2 Ϫ/Ϫ animals ( Table 1 ) (240, 391, 393). However, when metabolism is inhibited chemically, or with profound anoxia, the action potential shortens dramatically and contraction fails as a result of K ATP activation (66, 238, 419), both effects being absent when K ATP channels are ablated either by gene knockout of Kir6.2 (393) or treatment with a K ATP channel blocker (153, 419).
Activation of K ATP during ischemia is likely to be cardioprotective in vivo, since reduction of the APD and reduction of contraction may preserve ATP stores that would otherwise be consumed during the contractile cycle. In support of this idea, treatment with the K ATP opener pinacidil during ischemia increased the levels of cellular ATP and energy stored as creatine phosphate (269), and in Kir6.2 Ϫ/Ϫ hearts, the time to contractile failure is prolonged but the time to onset of contracture, which likely reflects the depletion of ATP (301), is reduced (393) . In addition to preservation of ATP, K ATP activation can reduce excessive Ca 2ϩ entry and its destructive sequellae, including arrhythmia, contractile dysfunction, and cell death (36). Increase in intracellular Ca 2ϩ in response to metabolic inhibition-reperfusion is exacerbated in both cardiac myocytes from Kir6.2 Ϫ/Ϫ animals relative to wild-type myocytes and in untransfected COS-7 cells (relative to cells expressing recombinant K ATP channels) (24, 30, 189, 190) . The increase in Ca 2ϩ during metabolic inhibition-reperfusion is correlated with cell death and membrane depolarization and is significantly blunted by activation of K ATP channels (23, 24, 189, 190) . Ca 2ϩ entry by reverse-mode Na ϩ -Ca 2ϩ exchanger activity is a major contributor to Ca 2ϩ overload during ischemiareperfusion (357) , and by reducing membrane depolarization, it is reasonable to predict that K ATP activation will minimize reverse-mode exchanger activity (23). Diastolic Ca 2ϩ overload, myocardial damage, and increased mortality are also observed in isoproterenol-challenged Kir6.2 Ϫ/Ϫ myocytes (461) . In this case, the L-type Ca channel inhibitor verapamil blocks the increased mortality and is consistent with the model that K ATP -dependent hyperpolariza-tion also suppresses Ca 2ϩ entry through voltage-dependent Ca 2ϩ channels in wild-type animals. Finally, evidence of "contractile dysfunctions" in skeletal muscle in the absence of K ATP (57, 58) gives further support to the conclusion that a major function of K ATP activation during metabolic stress is to reduce Ca 2ϩ entry by minimizing cell depolarization.
Although there is a generally accepted consensus that activation of K ATP within ventricular myocytes will be protective, there are some unexplained and unexpected findings that may require adaptation of the current model. For example, SUR1
Ϫ/Ϫ mice actually exhibit reduced infarct size and greater functional recovery following ischemia-reperfusion than wild-type mice (100). As discussed above, SUR1 is not normally a major component of mouse ventricular K ATP channel (100, 112, 127), suggesting that extraventricular K ATP channels, perhaps in neurons or in atria, contribute to increased infarct size through an as yet to be defined mechanism. Similarly, infarct size resulting from global ischemia is reduced in SUR2
Ϫ/Ϫ mice compared with wild-type mice (387) . Since K ATP channel activity in ventricular myocytes is essentially absent in SUR2 Ϫ/Ϫ mice, an extraventricular origin of protection is again postulated. Because SUR2 Ϫ/Ϫ mice also lack vascular smooth muscle K ATP , it is intriguing to speculate that persistant coronary vasospasm in these mice might generate a kind of preconditioning that helps protect the heart (see sect. IV). Consistent with this notion, the Ca channel blocker nifedipine reversed the cardioprotection evident in SUR2 Ϫ/Ϫ mice (387), potentially by blocking spontaneous vasospasm.
Cardiac K ATP channels and arrhythmia
Common electrocardiogram (ECG) findings during myocardial ischemia are a peaked T wave and elevation or depression of the ST segment, reflecting dispersion of repolarization. Consistent with activation of sarcolemmal K ATP underlying these features of the ECG during ischemia, both are blocked by the sulfonylureas glibenclamide and HMR1098 (40, 217, 229), and the K ATP channel opener pinacidil induces ST segment elevation in the absence of ischemia (229). Moreover, ischemia-induced changes in the ECG that are reminiscent of ST elevation are absent in Kir6.2 Ϫ/Ϫ mice (Table 1 ) (240), arguing strongly that K ATP channel activation causes ST segment elevation. It should be pointed out, however, that ST segment elevation also occurs in SUR2 Ϫ/Ϫ mice (see below) (54). This is surprising, since the absence of SUR2A leads to loss of ventricular K ATP and suggests that it may be the absence of SUR2 in vascular smooth muscle cells or elsewhere that is responsible.
Arrhythmias frequently accompany myocardial ischemia and reperfusion. Increased potassium conductance can stabilize the resting membrane potential, which may suppress ectopic pacemaker activity, but because K ATP channel activation also accelerates repolarization, shortening of the QT interval and reduced refractory period may actually predispose the heart to reentrant arrhythmias. Most studies (39, 52, 66, 369, 436), but not all (369) , indicate that pharmacological activation of K ATP promotes ventricular tachycardia and fibrillation, while channel blockers during ischemia-reperfusion generally decrease the incidence of sustained tachycardia and ventricular fibrillation (205, 436), but again not in all studies (369) . Pharmacological treatments used to tease out the effects of K ATP channels on cardiac rhythm have thus yielded equivocal results, but in general, K ATP activation should probably be considered proarrhythmic in the setting of ischemia.
Cardiac hypertrophy and heart failure in K ATP null mice
In response to a chronic stress such as hypertension, the complex pathological phenomena of cardiac hypertrophy and heart failure ensue. There is typically a progression of the heart from a compensated state characterized by myocardial growth and maintained cardiac output (i.e., cardiac hypertrophy), to a decompensated state in which cardiac contractility is depressed (i.e., dilated cardiomyopathy). Elevated intracellular Ca 2ϩ is a key component in the development of cardiac hypertrophy (433) ; activation of the calcineurin-NFAT signal transduction cascade by Ca 2ϩ drives the expression of hypertrophy genes. By virtue of their responsivity to changes in energy supply and their ability to regulate APD, Ca 2ϩ entry, and contraction, K ATP channels should tend to abrogate the disease process. Kir6.2 Ϫ/Ϫ animals do exhibit increased mortality and exaggerated hypertrophy in response to both pressure overload (163, 443) and to mineralocorticoid/salt challenge (202). Moreover, elevated intracellular Ca 2ϩ and increased calcineurin-NFAT activation are evident in Kir6.2 Ϫ/Ϫ myocytes compared with wild type following stress, consistent with the greater degree of hypertrophy (202, 443) . Cardiac function is also dramatically impaired in Kir6.2 Ϫ/Ϫ animals following hypertensive stress (i.e., transaortic constriction, mineralocorticoid/DOCA salt treatment): APD (443) and QT interval (202) are prolonged, indicating that K ATP may normally act to normalize the APD. Progression to congestive heart failure also appears to be more rapid in the absence of K ATP channels. Both animals with transaortic constriction (TAC) and Kir6.2 Ϫ/Ϫ animals treated with mineralocorticoid/DOCA salt exhibit increased pulmonary congestion and reduced fractional shortening (202, 443) . Taken together, these data suggest that K ATP may normally impede the myocardial death that is associated with the transition from hypertrophy to overt heart failure (91), such that in the absence of K ATP , heart failure is accelerated.
Importantly, K ATP channels respond differently to metabolic signals in the hypertrophied or failing heart compared with the normal heart. K ATP channels are less sensitive to inhibitory ATP in hypertrophied or heart failure myocytes (47, 224, 452), and in a transgenic tumor necrosis factor (TNF)-␣ mouse model of heart failure, K ATP channels responded poorly to metabolic inhibition (159), suggesting impaired metabolic control of channel activity. Reduced CK flux, a feature of the hypertrophic and failing heart (172), is observed in transgenic TNF-␣ mouse model (159), and in open cell-attached patches, K ATP channels are less responsive to creatine phosphate (159), suggesting that disruption of this phosphate shuttling pathway impairs ATP generation and hence channel activity in the TNF-␣ mouse model. Consistent with the hypothesis that impaired metabolic sensing by K ATP can affect the progression of heart failure, mutations (F1524S and A1513T) within the SUR2 gene locus that reduce the catalytic activity of NBF2, and should therefore reduce physiological activation of the channel, are associated with human dilated cardiomyopathy (38).
Finally, altered K ATP channels may also contribute to the metabolic phenotype of the failing heart. In a pressure overload model of heart failure, reduced K ATP channel activity impairs expression of the transcription coactivator PGC-1␣ (163), which controls expression of a number of metabolic enzymes (109). A recent proteomic comparison of wild-type and Kir6.2 Ϫ/Ϫ animals reveals a K ATPdependent subproteome (i.e., proteins that are differentially expressed in WT and Kir6.2 Ϫ/Ϫ myocardium), ϳ60% of which consists of proteins directly related to cellular metabolism (12, 463). These early studies suggest that feedback from K ATP activity to metabolism may turn out to be an important process in the chronic cardiac response to altered demands and associated disease processes.
Ischemic preconditioning and cardiac K ATP channels
Because K ATP channel activation can minimize the cell damage that results from ischemic or metabolic challenge, substantial effort has been devoted to exploiting the K ATP channel either pharmacologically or physiologically to improve cardiac function in disease states. Paradoxically, "preconditioning" of the heart by brief ischemic periods improves the recovery of contractile function and reduces the infarct size that results from a subsequent prolonged metabolic insult (290). That this effect can be blocked by glibenclamide has generated much interest in the cardioprotective role of K ATP channels (134). Preconditioning of the heart can be mimicked by a number of humoral factors, including adenosine (248, 445) and acetylcholine (447) . Blockade of adenosine-(445) and acetylcholine-induced preconditioning (447) with the K ATP channel blocker glibenclamide, coupled with the observation that the cardioprotective effects can be reproduced with K ATP channel openers (448), seemingly confirms a role for K ATP channels in preconditioning. However, a number of subsequent observations suggest an internal site of action in the mitochondria, leading to an ongoing debate over the distinct roles of sarcolemmal K ATP and mitoK ATP in protection from ischemia.
The first line of evidence that questioned a role for sarcolemmal K ATP channels in preconditioning was that cardioprotection by K ATP channel openers bimakalim, cromakalim, or pinacidil did not require shortening of the cardiac APD (138, 446 ). An additional line of argument arose from the observation that the channel opener diazoxide mimics ischemic preconditioning (122). Because diazoxide is relatively ineffective at opening ventricular sarcolemmal K ATP channels, but effective in stimulating mitoK ATP activity, the latter became a primary candidate cardioprotective factor. Finally, 5-hydroxydecanoic acid (5-HD), reported to block mitoK ATP (although initially described as a sarcolemmal K ATP blocker, Ref. 307), effectively abolishes ischemic preconditioning (253). These observations have been central to the argument that mitoK ATP , and not sarcolemmal K ATP , plays the major role in ischemic preconditioning.
However, one key assumption, that diazoxide is a specific opener for mitoK ATP and does not act on the sarcolemmal K ATP is incorrect: diazoxide has been shown to open sarcolemmal K ATP channels in ventricular myocytes at high concentrations (122) or when ADP concentrations are elevated (83), and it is now clear that sarcolemmal K ATP channels in the mouse atrium are exclusively diazoxide sensitive (112, 127). In light of these findings, the experimental conditions in preconditioning studies should be carefully reexamined to ensure that diazoxide is not activating sarcolemmal channels in the ventricle. Diazoxide has also been shown to inhibit succinate dehydrogenase (145), a key enzyme in both the electron transport chain and citric acid cycle and F 1 F 0 -ATPase function (67, 69), raising the possibility that diazoxide speeds ATP depletion during ischemia, providing cardioprotection by indirectly activating sarcolemmal K ATP channels.
Similarly, the idea that 5-HD is a specific blocker of mitoK ATP channels must also be carefully evaluated. An increase in flavoprotein oxidation occurs as a result of mitochondrial uncoupling, and 5-HD blocks the increase in flavoprotein oxidation during ischemia (161, 252). This finding, coupled with observations that 5-HD failed to block cromakalim-induced sarcolemmal K ATP activation and resultant APD shortening (268), has led to the assertion that 5-HD is a mitoK ATP specific blocker. However, 5-HD was initially described as a blocker of sarcolemmal K ATP channels in guinea pig ventricular myocytes (307) and has also been shown to both reduce extracellular K ϩ accumulation and to block APD shortening in the ischemic heart (283), all consistent with blockade of sarcolemmal K ATP channels (349) .
While there is certainly much work required to sort out the molecular details of ischemic preconditioning, it is important to note that both ischemic-and diazoxide-induced preconditioning are abolished in hearts from Kir6.2 Ϫ/Ϫ animals (392, 393) as well as in hearts with transgenic overexpression of ATP-insensitive Kir6.2 subunits (337) ( Table 1 ). Because the prevailing data indicate that Kir6.2 is not a subunit of mitoK ATP (see above), these findings provide further challenge to the primacy of mitoK ATP in preconditioning and argue that Kir6.2, and thus the sarcolemmal K ATP channel, is a critical player in cardiac preconditioning.
Catecholamine challenge and exercise in K ATP null mice
Most studies of K ATP channel regulation in vivo have focused on severe metabolic events (e.g., global ischemia or complete metabolic inhibition), but none has clearly identified the normal physiological events, or minimal metabolic stress, that cause channel opening. During exercise or catecholamine (e.g., isoproterenol) stimulation, increases in heart rate and contractility support the metabolic demands of skeletal muscle. Kir6.2 Ϫ/Ϫ mice exhibit reduced tolerance to treadmill stress and impaired survival in response to isoproterenol treatment ( Table 1 ), suggesting that cardiac K ATP normally activated during vigorous exercise and that it is required to support the increased work load (461) . The signal driving K ATP activation under these conditions could be decreased ATP and elevated ADP or agonist-dependent channel phosphorylation. The deleterious phenotype of the Kir6.2 Ϫ/Ϫ animals seems to result from two major outcomes. First, isoproterenol-induced action potential shortening is absent in the Kir6.2 Ϫ/Ϫ heart, implicating K ATP channels as key regulators of exercise-or stress-induced action potential shortening (461 Ϫ/Ϫ animals (388) , with no ST segment depression that is characteristic in the isoproterenol response of wild-type mice. It is thus not entirely clear that it is the lack of cardiac K ATP function that underlies the reduced exercise capacity in these animal models. Additional noncardiac benefits of exercise training which might contribute to increased exercise tolerance include a decrease in body weight and in fasting blood glucose. Interestingly, these features are observed in both wild-type mice and SUR2 Ϫ/Ϫ mice, but are absent in Kir6.2 Ϫ/Ϫ animals (203) ( Table 1 ). Since the latter additionally lack K ATP in the pancreas, altered pancreatic function may be the primary factor in this case and might ultimately underlie the exercise-induced cardiac dysfunction in Kir6.2 Ϫ/Ϫ animals.
III. K ATP IN SKELETAL MUSCLE
K ATP channels are also among the most densely expressed K ϩ channels in the skeletal muscle sarcolemma (382, 383) . Our understanding of the physiological role of the skeletal muscle channel has lagged behind that of its cardiac counterpart, and some counterintuitive observations using pharmacological agents to modulate skeletal K ATP activity were initially hard to reconcile. Nevertheless, recent studies of genetically altered mice reveal the important myoprotective role of sarcolemmal K ATP in skeletal muscle physiology.
A. Molecular Structure and Regulation of Skeletal Muscle K ATP
Higher levels of SUR2 expression than SUR1 in skeletal muscle (167, 168), together with observations that cromakalim and pinacidil (SUR2-selective openers) (4, 331) typically stimulate skeletal muscle K ATP channels better than diazoxide (SUR1-or SUR2B-selective opener) (28, 35, 424), have led to the general assumption that skeletal muscle K ATP channels are formed of Kir6.2 plus SUR2A subunits. The conclusion is further supported by loss of K ATP activity in skeletal muscles from Kir6.2 Ϫ/Ϫ (274) and SUR2 Ϫ/Ϫ (55) animals. However, more recent studies reveal that, as in the heart, skeletal muscle K ATP channel structure is more heterogeneous. With the use of a combination of electrophysiological and mRNA expression analyses, a recent study provided evidence that K ATP channel density and channel composition vary in different types of skeletal muscle (407) : K ATP channel density is higher in fast-twitch fibers than in slow type, and this is correlated with an increased expression of the Kir6.2 subunit. In addition, SUR1 expression is significantly higher in fast-twitch muscles, and these K ATP channels exhibit a characteristic diazoxide sensitivity indicative of a functional role for SUR1. Thus, as in cardiac muscle (112), it appears that while Kir6.2 is the predominant Kir6x isoform, both SUR1 and SUR2A are likely to play a role in the generation of functional channels, depending on the fiber type.
As in cardiac muscle, skeletal muscle K ATP channels remain predominantly closed at rest and do not contribute to electrical activity unless the muscle is stressed (165). Consistent with this idea, glibenclamide treatment has no effect on muscle excitability or contractility under normal resting conditions (265). Channel regulation by intracellular ATP and MgADP is similar to that in cardiac muscle (3, 382, 383, 420) , and metabolic inhibition similarly leads to activation of K ATP channels in the intact myocyte (5). Adenosine, which is released from metabolically compromised muscle, also stimulates skeletal muscle K ATP as it does in cardiac K ATP (27) . One notable distinction between cardiac and skeletal muscle K ATP channels is their regulation by intracellular pH. Cardiac channels are relatively insensitive to decreases in pH (75, 225, 237), while intracellular acidification is a potent activator of skeletal muscle K ATP (87, 88, 384).
B. K ATP in Physiology and Pathophysiology of
Skeletal Muscle: Insight From Genetically Modified Mice
Fatigue and exercise in K ATP null mice
Muscle fatigue is the decline in force production during prolonged and repetitive stimulation, and many biochemical mechanisms have been proposed to contribute to the fatigue process (6). One possible mechanism is that activation of K ATP channels, in response to reduction of ATP/ADP ratios, might underlie a decrease in action potential duration and hence twitch force. Consistent with this idea, application of cromakalim or pinacidil opens K ATP channels in skeletal muscle and accelerates the force failure in anoxic or fatiguing conditions (128, 129, 265, 430). However, glibenclamide, which will block K ATP channel activity, does not slow the decline of force during fatigue; instead, glibenclamide has no effect or may even accelerate the decline in tetanic force during fatigue, similar to channel openers (68, 244, 265, 415). Thus, paradoxically, both openers and blockers of K ATP can accelerate skeletal muscle fatigue.
Myographic examination of muscles from Kir6.2
and SUR2 Ϫ/Ϫ animals has helped to resolve this paradox. These studies reveal that the initial decline in force during fatigue is not typically associated with K ATP activation directly (hence glibenclamide does not slow fatigue development in wild-type skeletal muscle), but the activation of K ATP channels after fatigue has developed still helps to preserve a polarized membrane potential, protecting against voltage-dependent Ca entry and rise of (nonstimulated) tension that is observed in Kir6.2 Ϫ/Ϫ muscles (129) or glibenclamide-treated wild-type muscles (265) that are exposed to fatiguing stimuli (57, 58, 128, 130). This model accounts for the observation that the rate and extent of postfatigue recovery is decreased in both Kir6.2 Ϫ/Ϫ (57, 128, 129) and glibenclamide-treated muscle (130). Finally, the observation that there is extensive fiber damage in Kir6.2 Ϫ/Ϫ (203, 400) subjected to treadmill or swim training protocols reinforces the conclusion that K ATP channel activation is a physiologically relevant myoprotective mechanism in vivo, even though K ATP activation does not itself underlie the gradual loss of contractile activity in fatigue.
It remains to be seen whether these same phenotypes are found in SUR2 Ϫ/Ϫ mice, which also lack sarcolemmal K ATP , but initial studies suggest that this will be the case: extensive fiber damage, as in Kir6.2 Ϫ/Ϫ mice, is observed in trained SUR2
Ϫ/Ϫ mice (388). It is not clear whether mitoK ATP channels have a role in myoprotection. As in the heart, skeletal muscle can be preconditioned by ischemia or adenosine, and again, this process has been linked to mitoK ATP (286, 287, 314, 315) . However, detailed studies of skeletal muscle preconditioning have yet to be carried out on K ATP null mice, and these will be necessary to confirm a role for mitoK ATP .
Glucose uptake in K ATP null mice
A potentially interesting, but poorly understood, role of skeletal muscle K ATP is regulation of glucose uptake. It has been recognized for some time that treatment with sulfonylureas improves glucose homeostasis, independent of its effect on insulin secretion, by improving peripheral insulin sensitivity (86, 346, 386) . Skeletal muscle is a major site for insulin-stimulated glucose uptake, and sulfonylureas can enhance insulin-stimulated and basal glucose uptake into isolated skeletal muscle or L6 myotubes (330, 409, 423) . The conclusion that blockade of skeletal muscle K ATP channels increases basal or insulindependent glucose uptake is supported by studies of K ATP -deficient Kir6.2 Ϫ/Ϫ and SUR2 Ϫ/Ϫ animals (Table 1 ) (55, 274). In these mice, there is enhanced glucose uptake, consistent with an inhibitory effect of skeletal muscle K ATP activity on glucose uptake. It remains unclear precisely how K ATP regulates glucose uptake, but appears to be independent of the classical IRS-1/PI3-K signaling pathway (277).
A negative relationship between K ATP channel activity and glucose uptake potentially provides a negative feedback from electrical activity to the metabolic state of the cell and its substrate usage. It is intriguing to speculate that with increased K ATP channel activity (e.g., as will occur with K ATP mutations associated with neonatal dia-betes; Ref. 298), not only will insulin secretion from ␤-cells be reduced, but glucose uptake into skeletal muscle may also be limited, thereby exacerbating the hyperglycemic phenotype. Similarly, we may also speculate that in obesity an accumulation of fatty acyl CoA intermediates, by activating K ATP (249), will exacerbate insulin resistance (422) . ] i , respectively (294, 296). Thus modulation of membrane potential by both metabolic and humoral vasoactivators that act on K ϩ channels can have profound effects on smooth muscle tone. The primary focus of this section is on the role of K ATP in maintaining and regulating vessel tone in the prototypical smooth muscle, the vascular smooth muscle (VSM), and the possible cardiovascular consequences of altered VSM K ATP .
IV. K ATP CHANNELS IN SMOOTH MUSCLE
Multiple K ϩ channel types control electrical activity of the smooth muscle cell, including members of 1) the voltage-dependent K ϩ -channel family (K v ), 2) large-con- ductance Ca 2ϩ -activated K ϩ channels (BK Ca ), 3) two-pore domain K ϩ channel (K 2 P),
A. Vascular Smooth Muscle K ATP Structure
Deciphering the molecular composition of the K ATP subtypes in VSM has proven challenging. This is due to a number of factors, including the low density of K ATP expression in the vasculature (ϳ300 K ATP channels/cell in VSM vs. ϳ50,000 channels/cell in cardiac myocytes) (84, 300), the experimental difficulties in isolating and analyzing the electrophysiological properties of vascular smooth muscle cells (295, 312), and, most notably, the complex and variable biophysical and pharmacological properties of native VSM K ATP , which likely reflect differential expression of multiple K ATP subtypes in vascular beds (e.g., cororany arteries coexpress K ATP subtypes with varying conductances) (32, 41, 78, 195, 201, 281, 313, 385) . Early studies on native VSM K ATP from various sources demonstrated considerable variations in singlechannel conductances, even after accounting for different experimental conditions (65, 120, 280, 281, 313, 421, 456 ). Low-conductance channels (unitary conductances from 20 -50 pS) represent the predominant K ATP channel subtype, whereas medium-and high-conductance K ATP channels exhibit a more limited distribution in the vasculature (50 -70 pS and Ͼ200 pS, respectively) (64). Adding to the molecular complexity, K ATP channels from coronary arteries are reported to exhibit multiple subconductance states (313) . Unlike classic K ATP channels of the heart (1, 167) and pancreas (16, 168), the predominant VSM K ATP subtype is inactive in isolated membrane patches and requires nucleoside diphosphates (ADP, UDP, GDP) in the presence of Mg 2ϩ to open, leading to their functional designation as "nucleoside-dependent" K ϩ channels, or K NDP channels (32, 195, 456) .
Heterologously expressed Kir6.1/SUR2B channels recapitulate many of the salient biophysical properties of the native VSM K ATP /K NDP including 1) a lack of spontaneous channel activity upon membrane patch excision; 2) an obligatory requirement for di-and triphosphate nucleosides in the presence of Mg 2ϩ for activity; 3) a high sensitivity to the potassium channel openers (KCOs) pinacidil and nicorandil and to the inhibitory sulfonylurea glibenclamide; 4) a low unitary conductance of ϳ33 pS (145 mM external [K Ϫ/Ϫ and SUR2 Ϫ/Ϫ mice confirm an essential requirement for both Kir6.1 and SUR2 subunits in formation of VSM K ATP . In aortic smooth muscle isolated from Kir6.1 Ϫ/Ϫ and SUR2 Ϫ/Ϫ mice, pinacidil-and glibenclamide-sensitive K ATP currents are absent, whereas normal K ATP currents are observed in smooth muscle myocytes from both Kir6.2 Ϫ/Ϫ mice (54, 276, 391). Again, however, the conclusion that the Kir6.1/ SUR2B heteromultimer exclusively forms the ATP-sensitive K ϩ channel in VSM requires qualification. In addition to variations in the reported unitary conductances, a subpopulation of VSM K ATP in portal vein exhibits spontaneous activity in excised membrane patches and displays high sensitivity to inhibitory ATP (K 1/2 ϭ ϳ20 M) and a unitary conductance (49 pS in external K ϩ 60 mM) that is reminiscent of the cardiac K ATP channel (Kir6.2/SUR2A) (65, 305, 408, 456). Thus it is reasonable to conclude based on the current dataset that while the Kir6.1/SUR2B channel represents the predominant VSM K ATP , other subtypes are also likely to be expressed in specific vascular beds, separately or in combination with Kir6.1/SUR2B subunits (456) , and contribute to overall contractility. As discussed below, the VSM K ATP represents a clinically important target in the pharmacological control of vascular disease, and diversity of subunit makeup provides scope for vascular bedspecific agents. Diazoxide, an activator of SUR2B-containing channels (267), has long been recognized as a potent hypotensive agent in treatment of both acute (7, 401, 417) and pregnancy-induced hypertension (257), and understanding the molecular diversity and differential expression of K ATP subtypes will be important in further refining pharmacological approaches to target specific vascular beds and to treat hypertensive disorders (e.g., angina, hypertension, asthma).
B. Regulation of VSM K ATP and Implications for Vascular Tone
K ATP channels are tonically active in many vascular beds, including the coronary (94, 96, 166, 351) and mesenteric circulation (121, 293), and hence play a role in establishing basal tone in these vessels. This conclusion is based on the potent property of glibenclamide to depolarize and constrict isolated arteries (96, 121, 293, 351) and to increase coronary vascular resistance in perfused vascular beds under resting conditions in vivo (94, 175). Inhibition of the VSM K ATP channel will cause membrane depolarization, a sustained rise in intracellular [Ca 2ϩ ] (through both Ca 2ϩ influx and Ca 2ϩ release from intracellular stores), a decrease in arteriole diameter, and an increase in vascular resistance (280, 281, 421). Conversely, activation of K ATP channels leads to a lowering of intracellular Ca 2ϩ levels, an increase in arteriole diameter, and a decrease in vascular resistance (385, 435) . Not surprisingly, the VSM K ATP represents an important mediator in the vascular response of various pharmacological and endogenous factors (45).
Effects of endogenous vasodilators and vasoconstrictors on VSM K ATP
Vasoactive factors modulate VSM K ATP currents through activation of serine/threonine protein kinase pathways, including cAMP-dependent PKA, Ca 2ϩ -and phospholipid-dependent PKC (45), and possibly the cGMP-dependent protein kinase G (PKG) (334) . Adenosine, released from cardiac myocytes during hypoxia/ischemia, was the first vasoactive factor shown to directly activate VSM K ATP and to cause vasodilation through adenosine (A 2 ) receptor activation (34, 84, 85, 181, 210, 211, 272). Other endogenous vasodilators of note (Fig. 3) include the calcitonin generelated peptide (CGRP) released from sensory nerve endings (279, 293, 332, 429), ␤-adrenoreceptor agonists (208, 278, 291), vasoactive intestinal polypeptide (VIP) released from perivascular nerves, as well as nitric oxide (NO) (288) and the eicosanoid prostacyclin (PGI 2 ), both released from endothelial cells (183, 234) (Fig. 3) . Vasodilators that bind to G protein (G s )-coupled receptors [e.g., adenosine (A 2 ) receptor] activate intracellular adenylate cyclase (AC) leading to elevated cAMP levels, increased PKA activity, and direct phosphorylation and activation of the SUR2B-containing channel complex (336, 367) . PKA-mediated phosphorylation of SUR2B occurs at three key residues (Thr-633, Ser-1387, and Ser-1465) in the nucleotide-binding folds (NBF1, NBF2), and these modifications are postulated to enhance binding of stimulatory MgADP to the NBFs (336, 367) . Biochemical studies on isolated basilar (brain) and coronary arterial smooth muscle utilizing membrane permanent cAMP analogs and PKA-specific modulators confirm a central role of the PKA-K ATP axis in mediating the effect of endogenous vasodilators (208, 332, 429) , although the physiological action of vasoactive factors is complex and involves additional K ATP -independent pathways. For example, vasorelaxation of basilar and mesenteric arterial smooth muscle by CGRP is only partially reversed by glibenclamide (ϳ12-60% of the total current is glibenclamide insensitive) (209, 259, 293, 332), and a separate study reports virtually no effect of glibenclamide on CGRP-induced vasodilation in coronary arteries (194) . NO, which mediates its effect through the cGMP-PKG signaling pathway, may cause activation of K ATP in multicellular or intact systems (226, 288), although direct application of NO donors to smooth muscle cells has no obvious effect (334) , and direct evidence for phosphorylation of K ATP by PKG is lacking.
Conversely, endogenous vasoconstrictors act, in part, by inhibiting K ATP currents via the PKC signaling pathway (Fig. 3) , as evidenced by the ability of vasoconstrictors to reduce preactivated K ATP currents, but not in the presence of PKC inhibitors (64). Vasoconstrictor agonists that target VSM K ATP to promote contraction include the neurotransmitter serotonin (5-HT) (42, 211), the renalderived angiotensin II (150, 227, 280), endothelin-1 from endothelium (124, 281, 288, 316, 317), and proinflammatory histamine released from mast cells (42, 211), among others (Fig. 3) . Binding of vasoconstrictors to the G protein-coupled receptor subtypes, G i or G q , activates the PKC-isoform (150, 192, 352) . In turn, PKC--mediated phosphorylation of a serine-rich motif in the COOH terminus of Kir6.1 (S354, S379, S385, S391, and S397) results in both decreased frequency of channel openings (366) and a caveolin-dependent internalization of the Kir6.1/ SUR2B channel complex from the plasma membrane (185, 353). The net effect of PKC-mediated decrease in K ATP current (Fig. 3) is membrane depolarization and vasoconstriction (65, 335, 366, 402) .
Notably, the inhibitory action of angiotensin II on VSM K ATP involves not only activation of PKC signaling, but also suppression of steady-state PKA activity (150), implying a potential cross-talk between the positive (PKA) and negative (PKC) branches of the protein kinase signaling pathways in net regulation of VSM K ATP (Fig. 3) . Finally, alternative signaling pathways can potentially reg-ulate VSM K ATP activity and thereby modulate vascular tone. For example, the Ca 2ϩ -dependent phosphatase type 2B (PP2B), also known as calcineurin, inhibits K ATP in isolated aortic smooth muscle under conditions of elevated intracellular Ca 2ϩ (434) . The exact mechanism of PP2B action is unclear but may involve dephosphorylation of PKA-mediated phosphorylation sites on the channel (228, 457). In addition, K ATP in the retinal microvasculature is sensitive to the redox state of the cell, with oxidants from polyamine catabolism increasing K ATP activity and causing local vasodilation (176).
It is of course important to note that the integrated activity of all K ϩ channels types (K v , BK Ca , K ir ) ultimately establishes the membrane potential of smooth muscle cells and, hence, the contractile state. Since the activity of other K ϩ channels is modulated by endogenous vasoactive factors through PK signaling pathways [e.g., Kv currents are inhibited by endothelin-1 and angiotensin II (PKC) (151, 213, 370), whereas BK Ca channels are activated by NO (PKG) (345) and bradykinin (PKC) (118)], the net effect of PK modulation on VSM electrical activity will be complex.
ATP: a passive or dynamic regulator of VSM K ATP activity?
The hallmark of the archetypal K ATP channel is inhibition by ATP and stimulation by MgADP through direct interactions with the Kir6.x and SUR subunits, respectively (298). With respect to the VSM K ATP , intracellular nucleotides are clearly important in establishing the magnitude of K ATP /K NDP currents, since induction of hypoxia activates K ATP currents and induces a pronounced vasodilatation of coronary arteries (85, 338, 394). The hypoxic effect is presumably a consequence of a lowered ATP/ ADP ratio in the myocyte, and not necessarily secondary to release of vasoactive adenosine from the damaged cardiac tissue (85). Moreover, inhibition of metabolism with metabolic poisons (e.g., dinitrophenol, cyanide, and deoxyglucose), which lowers the ATP/ADP ratio, also activates whole cell K ATP currents in various smooth muscle cell types as well as in transfected cells expressing reconstituted Kir6.1/SUR2B (32, 70, 85, 108, 376, 454).
Nevertheless, it remains unclear what the adenosine nucleotide levels are in the VSM myocyte and whether ϩ -channel opener drugs (KCOs) (e.g., pinacidil and diazoxide) promote their antihypertensive effects by opening vascular smooth K ATP channels via interaction with the SUR2B subunit. Right: vasoconstrictor agonists that target VSM K ATP to promote contraction include the neurotransmitter serotonin (5-HT), angiotensin II, endothelin-1, and the proinflammatory histamine. Binding of vasoconstrictors to the G protein receptor subtypes G i or G q indirectly activates the PKC-isoform. In turn, PKC--mediated phosphorylation of a serine-rich motif in the COOH terminus of Kir6.1 results in a decrease in the frequency of channel openings. Ca 2ϩ -activated calcineurin (phosphatase type 2B) inhibits VSM K ATP , although the mechanism is unclear. Sulfonylurea compounds (e.g., glibenclamide) induce vasoconstriction by binding to the SUR2B subunit causing K ATP channel closure. cellular metabolism changes sufficiently to dynamically regulate VSM K ATP activity under physiological condition. We may speculate that ambient ATP and ADP levels establish a tonic level of VSM K ATP activity upon which vasoactive factors act (295). In this way, the K ATP channel will determine the basal tone by providing a steady "brake" on contractility, the strength of which is determined by the ambient ATP/ADP levels ( Fig. 3) 
(108).
Vasodilators and vasoconstrictors will then act to either increase or decrease the strength of the K ATP "brake," and hence the contractile state. The net contractility at any time will therefore be a summation of both vasodilatator and vasoconstrictor inputs. In metabolically inhibited states, such as hypoxia or ischemia, a fall in the intracellular ATP/ADP ratio will cause a resetting of the K ATP brake to favor vasodilatation [this pathology would apply to renal (256), cerebral (46, 338), and pulmonary arteries (432) where K ATP may not contribute to the basal tone, but rather the channel may serve a protective role by opening to promote vasodilation during severe hypoxia (59, 394, 432)]. Thus, while the ambient [ATP]/[ADP] ratio may establish a background level of K ATP activity, it may be the vasoactive cues that dynamically regulate the magnitude of VSM K ATP and, hence, the contractile state.
C. K ATP in Physiology and Pathophysiology of Vascular Smooth Muscle: Insight From Genetically Modified Mice
Hypertension in K ATP null mice
Mouse models in which the Kir6.1 and SUR2 genes have been "knocked out" highlight the critical role of K ATP in the cardiovascular system, particulary in the coronary circulation (54, 276). The cardiovascular phenotypes of Kir6.1 Ϫ/Ϫ and SUR2 Ϫ/Ϫ mice are similar (Table 1) and include baseline hypertension, coronary artery vasospasm, and sudden cardiac death, with 50% of Kir6.1 Ϫ/Ϫ and SUR2 Ϫ/Ϫ mice reportedly dying by ϳ6 and 27 wk of age, respectively. Electrocardiograms from both animals show marked ST segment elevation and AV block, which may account for the sudden death. Importantly, SUR2
Ϫ/Ϫ mice treated with nifedipine (which inhibits the voltage-sensitive Ca 2ϩ currents downstream of K ATP ) exhibit a reduction in coronary artery vasospasm, implicating abnormally elevated [Ca 2ϩ ] i due to loss of hyperpolarizing K ATP current as causal in the hypercontractility (54). Collectively, these K ATP -null mice recapitulate the clinical features of the human disorder of Prinzmetal (or variant) angina and predict that loss-of-function mutations in the VSM K ATP may be disease causing in humans (see below).
Vascular response to sepsis in K ATP null mice
During infection, the normal host immune response includes cytokine-induced systemic inflammation, or sepsis (62, 389). To meet the increased energetic demands during septic shock, the cardiovascular system responds through coronary artery vasodilatation to increase coronary circulation and oxygen delivery to the heart. The altered response of Kir6.1 Ϫ/Ϫ mice to induced endotoxemia (204) implicates the VSM K ATP in this adaptive vascular response. When immuno-stimulated with the endotoxin lipopolysaccharide (LPS) (Table 1), Kir6.1 Ϫ/Ϫ mice show a marked and persistent ST elevation (indicative of myocardial ischemic injury), a decrease in cardiac performance, and an increased mortality, indicating that loss of VSM K ATP predisposes Kir6.1 Ϫ/Ϫ mice to a significant survival disadvantage. Importantly, administration of the K ATP opener pinacidil (236) improves survivability in endotoxin-treated wild-type mice presumably by increasing coronary circulation, but has no effect on the survival rate in Kir6.1 Ϫ/Ϫ mice. A recent, unbiased screen of randomly ethyl-N-nitrosourea (ENU)-mutagenized mice for increased susceptibility to immunostimulatory agents has independently confirmed this critical role of Kir6.1 in mediating the vascular response to metabolic stress (74). Mutagenized mice with a loss-of-function mutation in Kir6.1 were identified based on their decreased survivability when challenged with mouse cytomegalovirus infection (74). In this same study, specific suppression of the SUR ortholog in Drosophila melanogaster by RNA interference similarly causes hypersensitivity to viral infection (74). It is intriguing to speculate that the baseline coronary vasospasm and sudden cardiac death in the initial studies of Kir6.1 Ϫ/Ϫ and SUR2 Ϫ/Ϫ mice (54, 276) may also reflect an impaired adaptive response, in this case, to metabolic stress in the course of normal pathogen exposure.
Role of extra smooth muscle K ATP in the control of vascular tone
While the hypertensive phenotype of both Kir6.1
and SUR2 Ϫ/Ϫ mice seemingly underscores the critical role of the VSM K ATP in controlling vascular tone, particularly in the coronary arteries and arterioles, this conclusion requires qualification. In addition to smooth muscle, Kir6.1 transcripts are detected in heart, lung, brain, pancreas, and endothelium (451) . Similarly, RNA transcripts for the SUR2 gene (ABCC9), which encodes the SUR2A and SUR2B splice variants, are found in multiple tissues, including cardiac and skeletal muscle (SUR2A) (56, 167), brain (SUR2A), and endothelium (SUR2B) (178). Thus the possibility exists that the cardiovascular phenotypes of Kir6.1 Ϫ/Ϫ and SUR2
Ϫ/Ϫ mice reflect loss of K ATP in both smooth muscle and nonsmooth muscle tissues (124). A role for non-smooth muscle K ATP in cardiovascular homeostasis is supported by the finding that targeted suppression of endothelial K ATP (Kir6.1/ SUR2B) by transgenesis results in an increase in coronary perfusion pressure and a decrease in coronary blood flow (184, 270, 451), a similar phenotype to that observed in Kir6.1 Ϫ/Ϫ mice (276). Interestingly, release of the vasoconstrictor endothelin-1 is increased by transgenic suppression of endothelial K ATP , potentially implicating an elevated level of circulating endothelin-1 as causal in the vasoconstriction. These studies raise the possibility of K ATP -dependent paracrine signaling between endothelial cells and overlying vascular smooth myocytes, with the endothelial K ATP regulating the release of endothelin-1, which then acts to inhibit the VSM K ATP . At present, the mechanism by which endothelial K ATP inhibits endothelin-1 release is unknown, although immunolocalization of the endothelial K ATP (Kir6.1) to intracellular organelles may indicate a role in the exocytotic machinery on endothelin-containing vesicles (260).
Further support for a potential role of non-VSM K ATP in regulation of vascular tone comes from additional mouse studies. Transgenic restoration of VSM K ATP currents by specifically expressing the SUR2B isoform in VSM of SUR2 Ϫ/Ϫ mice does not resolve the coronary artery vasospasm, AV heart block, or sudden cardiac death exhibited by SUR2 Ϫ/Ϫ animals (199). Although this result suggests the importance of a smooth muscle extrinsic process, the conclusion must be tempered by inability to confirm the extent of the restored K ATP activity, particularly in the microcirculation.
Taken together, the transgenic mouse studies implicate VSM K ATP (Kir6.1/ SUR2) as central in control of vascular tone, although K ATP in other cells types, such as the brain and endothelium, may also contribute. Generation of additional mouse models of altered K ATP in specific tissues will further help to define the interaction of nonvascular with vascular K ATP in regulating vascular tone.
D. Cardiovascular Disease and VSM K ATP : Where
Are the K ATP Mutations?
Mutations in the pancreatic ␤-cell K ATP channel (both the Kir6.2 and SUR1 subunits) underlie insulin secretory disorders in mice and humans (222). Heterozygous, activating mutations suppress glucose-induced insulin secretion from the ␤-cell and give rise to neonatal diabetes, whereas inactivating mutations result in unregulated secretion and underlie the corollary disorder of congenital hyperinsulinism (14, 135). This realization has led to a significant improvement in therapy options to treat insulin secretory disorders secondary to ␤-cell K ATP mutations (320, 323) . Given the high sequence and structural homology between Kir6.1 and Kir6.2 (75% amino acid identity), and with the assumption of similar mutation rates at the respective gene loci [Kir6.2 on 11p15. 1 (168) and Kir6.1 on 12p12 (104)], it is reasonable to predict that homologous mutations in Kir6.1 will occur naturally and cause pathology in humans. Specifically, on the basis of the coronary artery hypertension and coronary vasospasm described for Kir6.1 Ϫ/Ϫ and SUR2 Ϫ/Ϫ mice (54, 276), lossof-function VSM K ATP is predicted to underlie a Prinzmetal angina or similar phenotype in humans. Two recent genetic screens of Italian and Japanese cohorts diagnosed with impaired coronary vasoreactivity and coronary spastic angina, respectively, have failed to uncover associated Kir6.1 mutations (101, 404) . However, the impact of the studies was limited due to the small sample size in each case (n ϭ 18 or 19 patients) and failure to screen SUR2 (ABCC8) for associated variants. The Kir6.1 and SUR2 genes are located on human chromosome 12p (104), and chromosome 12p recombination has been shown to underlie autosomal-dominant hypertension (25), and postural hypotension is linked to chromosome 12 (146). Again, however, our recent analysis of Kir6.1 and SUR2 genes in a cohort of such patients failed to reveal any associate variants (99).
Nevertheless, there is increasing biochemical and genetic evidence linking the Kir6.1 and SUR2B isoforms with cardiovascular abnormalities, including the following: 1) association of a Kir6.1 variant (S422L) with ventricular fibrillation with prominent early depolarization (137), 2) a growth hormone-induced hypotension is associated with upregulation of Kir6.1 and SUR2B transcript levels in rat aorta (403) , and 3) both Kir6.1 and SUR2B protein expression are reduced in aortas from obese hypertensive (106) and spontaneously hypertensive rats (41), which may contribute to the hypercontractility. Comprehensive assessment of VSM K ATP as a risk or causal factor in cardiovascular disease will require both larger control-based studies with increasing power, as well as additional animal models of K ATP -induced vascular disease to identify potentially affected cohorts.
E. K ATP in Visceral Smooth Muscle
K ATP channels are also expressed in a variety of visceral (nonvascular) smooth muscle tissues, including gallbladder (458), stomach (180), esophagus (149), bladder (115), intestine (215), and uterus (254, 354). Although less well studied, the biophysical properties and physiology of visceral K ATP generally parallel those of VSM K ATP . As in the vasculature, there is significant heterogeneity of K ATP expression, with the predominant nonvascular K ATP subtype recapitulating the salient properties of the K NDP channel, including a low unitary conductance (ϳ40 pS), a requirement for NDPs for activation, and similar sensitivity to KCOs (pinacidil and diazoxide) (192, 215, 377, 397, 398, 453) . In addition to Kir6.1 and SUR2B, urethral myocytes express the Kir6.2 and SUR1 isoforms (453) , and there is evidence for heteromeric assembly of Kir6.1 with the Kir6.2 in a (Kir6.1) 3 -(Kir6.2) 1 arrangement with channels exhibiting intermediate channel behavior (399) . Co-lonic smooth muscle actually expresses Kir6.2 and SUR2B mRNA with no evidence for Kir6.1 transcript expression. A role for K ATP in regulating basal tone in visceral smooth muscle is evidenced by the ability of glibenclamide to increase tone and cause depolarization in multiple tissues including trachea (289), airway (200), and urethra (396) . Surprisingly, perhaps, there are no reports of nonvascular smooth muscle dysfunction (e.g., altered myometrial contractility during parturition, or nutrition deficits due to impaired gastrointestinal function) in either Kir6.1 Ϫ/Ϫ or SUR2 Ϫ/Ϫ mice (54, 276). Whether the lack of a phenotype reflects compensatory K ϩ channel expression in nonvascular smooth muscle, or more subtle physiological consequences of K ATP ablation, remains unclear.
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